CytoDyn (OTCQB:CYDY) will be coordinating
with the National Institutes of Health (NIH) of Mexico and providing
leronlimab for a trial for the severe/critical COVID-19 population in
Mexico, with the potential to collaborate on further CytoDyn COVID-19
trials.
The study is anticipated to consist of ~30 patients with potential involvement of the NIH of Mexico in other CytoDyn trials.
CytoDyn is currently enrolling a Phase 2b/3
clinical trial for 390 patients and Phase 2 trial with 75 patients in
the mild-to-moderate COVID-19 population.
https://seekingalpha.com/news/3575831-cytodyn-and-mexican-nih-team-up-to-evaluate-leronlimab-for-treatment-of-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.